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Summary 
This review aimed to assess the impact of behavioural therapy for insomnia administered alone (BT-I) 
or in combination with cognitive techniques (cognitive-behavioural therapy for insomnia, CBT-I) on 
depressive and fatigue symptoms using network meta-analysis. PubMed, Scopus and Web of Science 
were searched from 1986 to May 2015. Studies were included if they incorporated sleep restriction, 
a core technique of BT-I treatment, and an adult insomnia sample, a control group and a 
standardised measure of depressive and/or fatigue symptoms. Face-to-face, group, self-help and 
internet therapies were all considered. Forty-seven studies were included in the meta-analysis. 
Eleven classes of treatment or control conditions were identified in the network. Cohen’s d at 95% 
confidence interval (CI) was calculated to assess the effect sizes of each treatment class as compared 
with placebo. Results showed significant effects for individual face-to-face CBT-I on depressive (d= 
0.34, 95% CI: 0.06 - 0.63) but not on fatigue symptoms, with high heterogeneity between studies. 
The source of heterogeneity was not identified even after including sex, age, comorbidity and risk of 
bias in sensitivity analyses. Findings highlight the need to reduce variability between study 
methodologies and suggest potential effects of individual face-to-face CBT-I on daytime symptoms. 
 
Keywords: insomnia; depression; fatigue; CBT; network meta-analysis.  
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Abbreviations 
BT-I= behavioural therapy for insomnia including sleep restriction strategy alone or in combination 
with other behavioural techniques 
CBT-I= cognitive behavioural therapies for insomnia combining behavioural therapy, cognitive 
therapy, and psychoeducation for insomnia 
CI= confidence interval  
DF= degrees of freedom 
PRISMA= preferred reported items for systematic reviews and meta-analysis 
RCT= randomised controlled trial 
SC= stimulus control  
SR= sleep restriction 
 
Glossary of terms 
Network meta-analysis: statistical method that evaluates the effectiveness of multiple treatments 
simultaneously combining direct and indirect evidence of treatment differences within a structure 
called network.  
Net graph: graphical tool which depicts the geometry of the network. It consists of nodes 
(representing treatments) and edges (representing direct comparisons between treatments).  
Inconsistency: network meta-analysis assumes that direct and indirect evidence of treatment 
difference is consistent. Consistency means that indirect evidence of difference between any two 
treatments in the network do not differ from the direct evidence, i.e. the assumption that direct and 
indirect evidences are similar in factors that could affect the relative treatment effects.  
Net heat plot: graphical tool to detect inconsistency in the network. The grey squares indicate the 
amount of contribution of the direct estimate in design (shown in the column) to the network 
(shown in the row). Colours are related to the degree of inconsistency between direct and indirect 
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evidence for the corresponding design. Blue colours indicate low level of inconsistency, while red 
colours indicate “hot spots” of high inconsistency. 
Forest plot: graphical representation of meta-analysis results.  
Heterogeneity: variability in the distribution of effect sizes of the studies included in a meta-analysis. 
Sleep restriction: behavioural intervention for insomnia which consists of initially reducing time in 
bed with the aim of enhancing homeostatic sleep pressure. Time in bed is then adjusted on a weekly 
basis based on average sleep efficiency of the preceding week.  
Stimulus control: behavioural intervention prescribing patients to use their bed only for sleeping, to 
go to bed only when they are sleepy, and not to use their bedroom for anything but sleep.  
Cognitive therapy: cognitive interventions consisting of cognitive restructuring, problem solving and 
cognitive control techniques. 
Sleep hygiene education: sleep-promoting behaviours such as avoiding naps, caffeine and/or alcohol 
intake and physical activity right before sleeping.  
Relaxation therapy: behavioural interventions including progressive muscle relaxation and autogenic 
training aimed to decrease the levels of arousal. 
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Introduction 
Daytime symptoms of insomnia, particularly depressive and fatigue symptoms, are often the reason 
insomnia patients seek help [1]. Nevertheless, neither frequency, duration, nor intensity criteria are 
available for these symptoms. The gold standard for psychological treatment of insomnia is 
behavioural intervention administered alone (BT-I) or in combination with cognitive techniques 
(cognitive-behavioural therapy for insomnia CBT-I)[2]. However, it is unclear to what extent BT-I 
and/or CBT-I is effective for depressive and fatigue symptoms. The aim of the present study was to 
address this gap in the literature by performing a systematic review and network meta-analysis on 
the effectiveness of BT-I and CBT-I on daytime depressive and fatigue symptoms.  
Behavioural and cognitive behavioural therapies for insomnia 
BT-I and CBT-I are, at present, the gold standard for psychological treatment of insomnia [2]. BT-I 
includes two main interventional strategies: sleep restriction (SR) and stimulus control (SC). Both 
strategies have been shown to be effective for insomnia even if delivered as standalone treatments 
[3].  
BT-I is often delivered with cognitive interventions and/or sleep hygiene psychoeducation protocols 
[3]. BT-I and CBT-I can be administered face-to-face individually or in group settings, as well as 
through self-help using the internet or booklets.  
Depressive symptoms in insomnia  
Individuals with insomnia often complain of negative mood or subclinical depression (e.g. [4]). A 
meta-analysis of epidemiological longitudinal studies found that insomnia is a predictor of the onset 
of depressive disorder [5]. Thus, reducing subclinical depression reported by those with insomnia 
through sleep therapy may also have a potential preventive impact on the incidence of major 
depression [6].  
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Previous meta-analyses of randomised controlled trials (RCTs) of self-help [7-9] and group [10] CBT-I 
showed promising results on self-reported depressive symptoms. However, there are several 
limitations to previous meta-analyses. First, previous research has been limited to pairwise 
comparisons using traditional meta-analysis. Comparative effectiveness reviews usually include only 
one subset of all potential comparisons between the arms of a trial. Consequently, previous studies 
have not compared the effects of different therapeutic settings (e.g. face-to-face, group, self-help 
CBT-I). Second, to our knowledge, no meta-analysis investigating the efficacy of individual face-to 
face CBT-I for alleviating depressive symptoms has been conducted [11]. 
Fatigue symptoms in insomnia 
Fatigue has been reported as one of the most frequent complaint of patients with insomnia [12]. 
Thus, there is a need to clarify the extent to which standard treatment for insomnia is effective in 
reducing fatigue, with a view to improving patients’ quality of life. Recent RCTs suggest that treating 
insomnia with psychotherapy also reduces fatigue symptoms [13]. However, to the best of our 
knowledge, no meta-analysis assessing the efficacy of BT-I or CBT-I on fatigue symptoms has been 
conducted.  
Network meta-analysis 
Systematic reviews are important tools for summarising scientific evidence, particularly in clinical 
interventions, where the benefits and harms of the available treatments for a given medical 
condition need to be identified in order to adequately develop and implement evidence-based 
clinical guidelines and practice. In the past, meta-analyses were mostly based on pairwise 
comparisons investigating the effectiveness of one treatment against one control condition. In recent 
years, however, meta-analytic reviews have gradually evolved to evaluate the effectiveness of 
multiple treatments simultaneously [14]. This has led to the application of more sophisticated 
synthesis methods able to simultaneously compare the effectiveness of multiple treatments, 
generally referred to as network meta-analysis or mixed treatment comparison [15]. In the context of 
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evidence-based medicine, network meta-analysis aims to compare a number of available treatments 
for a given diagnosis by combining direct and indirect evidence on treatment effects based on a 
common comparator [16]. Network meta-analysis is a valid statistical method which allows for 
simultaneous analysis of both direct and indirect comparisons among multiple treatments across 
multiple studies. This method has advantages over pairwise meta-analysis, including: a) borrowing 
strength from indirect evidence to compare all treatments; b) estimating comparative effects that 
have not been investigated head-to-head in RCTs; c) comparing between different interventions for 
one condition which informs clinical practice [17,18].  
To explain the conceptual underpinning of network meta-analysis, and specifically the meaning of 
direct and indirect evidence, suppose we compare two active treatments, A and B, and a control 
condition, C. Given direct evidence from studies regarding the difference of treatment effects for A 
and C and evidence regarding the difference of treatment effects for B and C from other studies, 
these studies also provide indirect evidence for treatments A and B. Therefore, the aim of network 
meta-analysis is to estimate the treatment differences and associated standard errors combining 
direct and indirect evidence [16]. With respect to pairwise meta-analyses, network meta-analyses 
allow for visualisation of a larger amount of evidence, and estimation of the relative effectiveness 
among all treatments, even if some comparisons are absent [19]. For this reason, network meta-
analysis increases power and precision as compared to pairwise meta-analyses [20]. For network 
meta-analyses to be possible, important assumptions have to be met. It is assumed that direct and 
indirect evidence of treatment difference maintain transitivity, i.e., included trials are similar in 
factors that could affect the relative treatment effects. Furthermore, it is assumed homogeneity of 
the network, that is, the effects estimates of studies with similar designs (i.e. comparing the same 
interventions) are similar. Finally, consistency of the network is required, i.e. indirect evidence of 
difference between any two treatments in the network do not differ from the direct evidence. 
Inconsistency within treatments network is assessed through net heat plot [21], a graphical tool that 
represents changes in heterogeneity due to relaxing the consistency assumption for single designs in 
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a matrix visualisation. Although valid, the network approach is not free of limitations. For instance, 
Mills [22,23] highlighted how most networks have unbalanced designs, that is, many trials are 
present for some comparisons whereas there are few or none for other comparisons. Consequently, 
evidence may be of high quality for some treatments and comparisons but of low quality for others 
[22,23].  
Study aim 
Previous pairwise meta-analyses have primarily focussed on night-time symptoms of insomnia and 
only few have examined the effectiveness of CBT-I on daytime symptoms [7-10]. Therefore, the 
present review aimed to provide a qualitative and quantitative synthesis of the effectiveness of BT-I 
and CBT-I, defined by including at least SR, in reducing depressive and fatigue symptoms reported by 
patients with insomnia. A decision to focus on SR was made because it is a core evidence-based 
behavioural technique for the treatment of night-time symptoms of insomnia [24,25]. SR is the only 
psychological intervention for insomnia which has been systematically assessed for standardisation 
[24]. For this reason, and in order to minimize the risk of heterogeneity within the tested treatments, 
a decision was made to include all studies that include SR. 
Methods 
This study was conducted according to the Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA) guidelines [14] (a table of contents of supplementary material is reported in 
Document S1, see PRISMA check-list in Document S2). 
Literature search 
To identify the papers for this review, we first considered all studies included in the systematic 
review on the implementation of SR for insomnia by Kyle et al. [24], where authors searched relevant 
BT-I and CBT-I trials including at least SR in PubMed, Scopus and Web of Science from 1986 to June 
2014. Using this database, we updated the searches using the same search engines from June 2014 
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to May 2015. Search terms were: “cognitive therapy” or “cognitive behavior* therapy” and 
“insomnia” or “sleep initiation and maintenance disorder”. Further, we expanded our search through 
hand searching the references of the screened full-texts. The second author conducted the literature 
search. The first and the second authors independently screened titles and abstracts for the inclusion 
as well as full texts’ reference list. Final selection of articles was discussed by the first and last 
authors.  
Inclusion and exclusion criteria 
To be included, studies had to fulfil each of the following inclusion criteria: 1)RCTs ; 2) published in 
English; 3) incorporating at least SR or sleep compression in the treatment; 4) an adult insomnia 
sample; 5) a standardised measure of depressive and/or fatigue symptoms. Controlled studies 
consisting of CBT-I combined with other therapies (i.e. CBT-I and pharmacotherapy, CBT-I and 
mindfulness therapy) were excluded. To examine differences in the effectiveness of different 
therapeutic settings, studies using different types of CBT-I administration (individual therapy, group 
therapy, self-help therapy) were included. Unpublished studies were excluded. 
Data extraction 
For each selected study, socio-demographic, clinical and methodological variables were extracted. 
Risk of biases was assessed through a checklist derived from the integration of the quality 
assessment tool for quantitative studies [26] and the Cochrane Collaboration’s tool for assessing risk 
of bias [27] (see Document S3). Since the weight of the conclusions drawn from meta-analytic 
reviews largely depends on the validity of the findings of single studies included, it is essential to 
assess study quality [27]. The tool used in the present review assessed the following potential areas 
of bias: 
1) Selection bias: evaluation of recruitment and randomisation methods;  
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2) Blinding of outcome assessment: evaluation of awareness of outcome assessors of 
intervention or exposure status of participants;  
3) Incomplete outcome data: evaluation of withdrawals and dropouts. This item does not assess 
whether the risk of dropout is related to treatment. 
4) Other sources of bias: 
a. Confounders: evaluation of important differences between groups prior to the 
intervention on confounding variables (e.g. race, sex, marital status, age, health 
status); 
b. Data collection methods: evaluation of validity and reliability of instruments. 
The first and the second authors independently rated each study, and disagreements were resolved 
through consensus discussion. The final score identified whether a study was either at low, moderate 
or high risk of bias. After data extraction, treatments were grouped into six CBT-I classes and five 
control conditions:  
1) BT-I individual: behavioural therapy for insomnia face-to-face in individual setting; 
2) BT-I group: behavioural therapy for insomnia in group setting; 
3) BT-I self-help: behavioural therapy for insomnia in self-help setting; 
4) CBT-I individual: behavioural and cognitive therapy for insomnia face-to-face in individual setting; 
5) CBT-I group: behavioural and cognitive therapy for insomnia in group setting; 
6) CBT-I self-help: behavioural and cognitive therapy for insomnia in self-help setting including 
internet interventions, booklets with and without phone consultations, video and audiocassette 
instruction and classes; 
7) Pharmacological: including not only sleep drugs or antidepressant, but any medication used as a 
treatment or control condition;  
8) Sleep hygiene: including sleep hygiene education alone, which is associated with limited 
effectiveness [28]; 
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9) Placebo: including both placebo pills and behavioural placebo such as self-monitoring of sleep 
with and without professional help and quasi-desensibilization placebo technique; 
10) Psychological: including relaxation, mindfulness, tai chi, stress management, CBT for pain, CBT 
for depression; 
11) Waiting list: including both waiting list and no intervention.  
Pre- and post- treatment means and standard deviations of self-reported questionnaires of 
depression and/or fatigue, for both experimental and control groups were extracted by the first 
author to calculate effect sizes as standardised mean differences. When means and standard 
deviations were not reported in the articles, effects sizes were calculated from other indexes such as 
standard errors, root mean square deviations, quartiles and degrees of freedom (DF).   
Statistical analyses 
Effect sizes (Cohen’s d) were estimated for groups’ differences with respect to change from baseline.  
For each study, we used data from participants who completed post-treatment assessments. Meta-
analytic calculations were performed using the statistical software package R (http://www.R-
project.org/). We performed a frequentist network meta-analysis [29] using the R-package 
“netmeta” [30]. All classes of intervention were compared against placebo, considered a preferable 
reference condition [31]. A random-effects model was used because of the considerable 
heterogeneity between studies (e.g. different populations, settings, etc.). To test network 
heterogeneity, Cochran’s Q and Higgins’s I
2 
were calculated. Cochran´s Q is computed as a weighted 
sum of squared differences between single study effects and the pooled effect across studies. 
Significant values indicate a high level of heterogeneity between effects that need to be further 
investigated. Higgins’s I
2 
assesses the variability in effect estimates that is due to between-study 
heterogeneity rather than due to chance. Low percentages of I
2
are indicative of low heterogeneity 
while percentages over 75% represent considerable levels of heterogeneity [32]. 
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To assess the geometry of the network, the netgraph function of “net-meta” package was used. 
Additionally, net heat plots [21] have been used to detect “hot spots” of inconsistency among 
comparisons. The contribution of pooled direct evidence of each single design (shown in column) to 
each network estimate (shown in row) is represented by the area of the grey squares. The colours of 
the diagonal represent the intensity of inconsistency of the network, with red squares (hot spots) 
indicating greater inconsistency and blue squares indicating less inconsistency. 
To investigate the source of heterogeneity, sensitivity analyses were conducted by selecting or 
excluding groups of studies depending on possible confounding variables. This allows for effect sizes 
of different treatments in specific groups of studies such as those with only comorbid insomnia or 
single sex samples to be compared. Possible sources of variance accounted for in the network were: 
self-help with or without professional contact, comorbidity, sex, age, and risk of bias. 
Results 
Database searching 
Database searching yielded 1076 abstracts (Scopus n=629, PubMed n=258, Web of Science n=188). 
Of these, 48 studies were included in systematic review while 47 were entered in the meta-analysis. 
One study was excluded from the analysis because the CBT-I treatment was administered in two 
phases and modes: first in group format and then individually [33]. Therefore, it did not fit the 
treatment categories identified in this review. The aggregated sample size is as follows: 2448 
insomnia patients who underwent CBT-I and 1869 controls. The study selection flowchart is reported 
in Figure 1. Excluded studies and reasons for exclusion are reported in Table S1. 
 
Please insert figure 1 here. 
Study characteristics  
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A summary of the included studies is reported in Table 1. Additional qualitative information is 
reported in Table S2. Risk of bias assessment data is reported in Table S3. The mean age of 
participants in the included studies was 51.9 years and mean percentage of females was 62.8. CBT-I 
was administered individually in 16 trials [34-49], in group in 10 trials [50-59] and through self-help in 
17 trials [35,45,60-74]. BT-I was administered individually in two trials [75,76], in groups in two trials 
[77,78] and through self-help in two trials [79,80].  
Thirty-nine studies measured depressive [34-48,50-53,55-64,66,67,69,71,72,74,75,77,79,80] while 22 
studies measured fatigue [34,41,43-45,47,49,51,53-55,58,59,62,64,65,68,70,73,78,79] symptoms as 
outcome measures. The majority of  studies (n=13: [34,35,37,38,40,46,50,57,58,62,67,69,80]) 
measured the presence and severity of depressive symptoms through the Beck depression inventory 
[81]. Nine studies [39,43,45,47,51,56,59,60,64] measured depressive symptoms using the hospital 
anxiety and depression scale [82], and 4 [36,41,52,71] using the profile of mood states [83]. Three 
studies [66,72,79] used the centre for epidemiologic studies-depression scale [84] and 1 the revised 
form of this questionnaire [44]. Two studies [74,77] used the geriatric depression scale [85], 1 study 
[63] used the depression anxiety stress scale [86] and 1 study [75] the Hamilton rating scale for 
depression [87].  
With respect to fatigue, the majority of  studies (n=11: [34,44,45,47,53,55,59,64,70,73]) assessed the 
presence and severity of symptoms using the multidimensional fatigue inventory [88] while 5 studies 
[49,58,62,68,78] used the fatigue severity scale [89]. Furthermore, 1 study [79] measured fatigue 
through the fatigue/inertia subscale of the profile of mood states [83], 1 [41] through the chronic 
respiratory disease questionnaire fatigue scale [90], 1 [54] through the Flinder fatigue scale [91], 1 
[43] through the Piper fatigue scale [92], 1 [51] through the fatigue symptom inventory [93], 1 [76] 
through a subscale of an insomnia symptom questionnaire and 1 through a specific daytime fatigue 
scale [65]. 
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Please insert Table 1 here. 
 
Network meta-analysis results 
Depressive symptoms 
Considering depressive symptoms, the network was based on 57 pairwise comparisons. The net 
graph is shown in Figure 2. Original data with estimated effects, standard errors and adjusted 
standard errors for multi-arm trials are reported in Document S4. 
 
Please insert Figure 2 here. 
Comparing each class of treatment with placebo, results showed significant mean effects of CBT-I 
individual with an effect size of medium magnitude (d= 0.46, 95% CI: 0.19 - 0.73). No significant 
effects were found in relation to other treatments. Q and I
2 
tests revealed high heterogeneity 
between studies (Q= 167.24, df= 38, p<0.0001; I
2
= 77.3%) and net heat “hot spots” indicated 
inconsistency in the network as shown in Figure 3. 
 
Please insert Figure 3 here. 
 
The net heat graph suggests that the design that mostly contributed to this inconsistency involved 
the three edges: CBT-I individual-psychological-waiting list. Direct evidence for two of these (CBT-I 
individual-psychological and psychological-waiting list) was associated with only one study [44]. Thus, 
this study was excluded from the analyses performed. Significant effects remained for CBT-I 
individual (d= 0.43, 95% CI: 0.17 - 0.69), with a decreased, but significant level of heterogeneity (Q= 
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153.71, df= 36, p<0.0001, I
2
= 76.6 %). Consequently, we considered the second design that mostly 
contributed to inconsistency, which consisted of the following edges: CBT-I individual-
pharmacological-sleep hygiene. Thus, we excluded all edges including this design [36,38,45] from the 
analyses. Significant effects were found only for CBT-I individual (d= 0.41, 95% CI: 0.15 - 0.67), with a 
significant level of heterogeneity (Q= 112.89, df= 31, p<0.0001, I
2
= 72.5%). By further excluding the 
third design contributing to the inconsistency in the network with the edge CBT-I individual-waiting 
list [37,39,42,45] we still observed significant effects for CBT-I individual (d= 0.34, 95% CI: 0.06 - 
0.63). Levels of heterogeneity decreased although these remained significant (Q= 64.14, df= 22, 
p<0.0001, I
2
= 65.7%). “Hotspots” of inconsistency were absent from the net heat plot as shown in 
Figure 4. A forest plot exploring this more consistent network is presented in Figure 5.  
 
Please insert Figure 4 here. 
Please insert Figure 5 here. 
To investigate other potential sources of heterogeneity, further sensitivity analyses were conducted. 
First, analyses were performed considering the clinical characteristics of the studies’ samples. 
Specifically, data analysis included only studies which excluded any form of psychiatric and/or 
medical condition (including other sleep disorders) co-occurring with insomnia. Twelve studies were 
deemed suitable for analysis [37,56,57,63,60,66,67,69,70,72,77,80]. Results indicated no significant 
effects on depressive symptoms for any treatment. However, studies included in this analysis either 
identified the presence of depression as part of their inclusion criteria, or obtained samples with low 
levels of pre-treatment depression. With respect to heterogeneity, Q value decreased while I
2
 tests 
indicated considerable presence of heterogeneity (Q= 19.61, df= 4, p<0.0006, I
2
= 79.6%).  
Therefore, our analyses included only studies with comorbid insomnia samples, comprised of 28 
studies [34-36,38-48,50-53,55,58,59,61,62,64,71,74,75,79]. Results indicated a significant effect for 
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CBT-I individual (d= 0.41, 95% CI: 0.11 - 0.71) with high levels of heterogeneity (Q= 97.52, df= 26, 
p<0.0001, I
2
=73.3%). No significant effects were found relating to other treatments.  
Second, we considered other possible sources of heterogeneity such as sex and age. Six studies had 
exclusively female samples [43,45,56,58,59,79]. Because studies were too few to perform a network 
meta-analysis, we indirectly evaluated the effect of this group of trials by excluding this group from 
the analyses. A significant mean effects for CBT-I individual of medium magnitude (d= 0.47, 95% CI: 
0.17 - 0.76) was found. However, Q and I
2 
tests revealed high levels of heterogeneity between the 
remaining studies (Q= 127.44, df= 29, p<0.0001, I
2
= 77.2%). 
Six studies [53,57,71,74,75,77] included exclusively elderly samples (i.e. age >60 years or defined as 
older adults sample in the title). Again there were too few studies to warrant a network meta-
analysis; we indirectly evaluated the effect of this group of trials by excluding this group from the 
analyses. Results indicated significant effects of CBT-I individual (d= 0.45, 95% CI: 0.19 - 0.72). Q and 
I
2
 tests revealed high levels of heterogeneity (Q=139.47, df= 33, p<0.0001, I
2
= 76.3%). 
To indirectly analyse the efficacy of self-help with or without professional contact, sensitivity 
analyses were conducted, excluding specific groups of studies. First, analyses were performed 
excluding studies which used self-help with contact [35,61,64,65,72,67]. A significant effect for CBT-I 
individual (d= 0.47, 95% CI: 0.19 - 0.75) with high heterogeneity (Q=147.58, df= 32, p<0.0001, I
2
= 
78.3%) was found. Second, analyses were performed excluding studies which used self-help therapy 
without professional contact [45,60,62,63,66,69,80]. Results indicated significant effects for CBT-I 
individual (d= 0.38, 95% CI: 0.07 - 0.70) with decreased but significant levels of heterogeneity 
(Q=112.19, df= 28, p<0.0001, I
2
= 75%). 
Finally, analyses were conducted excluding the study evaluated at high risk of bias [67]. Results 
indicate a significant effect for CBT-I individual of medium magnitude (d= 0.47, 95% CI: 0.20 - 0.73), 
with high heterogeneity maintained (Q= 162.86, df= 37, p<0.0001, I
2
= 77.3%).  
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It was not possible explore the impact of depression instrument on heterogeneity due to a small 
number of studies. Nevertheless, it was possible to indirectly evaluate the effect of the Beck 
depression inventory, the most frequently used instrument, by excluding 13 studies using this scale 
[34,35,37,38,40,46,50,57,58,62,67,69,80] from the analysis. Results still indicated a significant effect 
of CBT-I Individual on depression (d= 0.65, 95% CI: 0.23 - 1.06), with high and significant levels of 
heterogeneity (Q= 115.37, df= 21 p< 0.0001, I
2
= 81.8%). Forest plots for all analyses are reported in 
Document S5.  
To further explore the possible contribution of depression instrument in determining high 
heterogeneity between studies, we estimated whether the instruments were unequally distributed 
over the three comparisons; CBT-I Individual vs BT-I Individual, CBT-I Group vs BT-I Group, CBT-I Self-
help vs BT-I Self-help. Fisher’s exact test revealed no association between comparisons (p=0.546).  
Fatigue symptoms 
Considering fatigue, the network was based on 32 pairwise comparisons. The net graph is shown in 
Figure 6. Original data with estimated effects, standard errors and adjusted standard errors for multi-
arm trials are reported in Document S6. 
 
Please insert Figure 6 here. 
 
Comparing each treatment category with placebo, significant effects for CBT-I individual (d= 0.45, 
95% CI: 0.07 - 0.83) were found. Q and I
2 
tests revealed high heterogeneity between studies (Q= 
72.23, df 17, p<0.0001; I
2
= 76.5%) and net heat “hot spots” indicated inconsistency in the network as 
illustrated in Figure 7. 
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Please insert Figure 7 here. 
 
Net heat graph data indicates that the design with greatest contribution to inconsistency involved 
the three edges CBT-I group-pharmacological-placebo. Direct evidence for this (CBT-I group-placebo 
and-waiting list) was drawn from two studies [51,58]. Thus, we excluded them from the analyses. 
Results showed significant effects for CBT-I individual (d= 0.39, 95% CI: 0.02 - 0.75), with Q and I
2 
tests indicating reduced but significant heterogeneity among studies (Q= 48.96, df= 14, p<0.0001, I
2
= 
71.4%). The second design with greatest contribution to inconsistency, consisted of the following 
edges: CBT-I individual-psychological-waiting list. Consequently, we excluded all the edges defining 
this design [44,45] from the analyses. No significant effects across all treatments were found. 
Heterogeneity, although reduced, remained significant (Q= 36.63, df= 10, p<0.0001, I
2
= 72.7%). Net 
heat plot showed no more “hot-spots” of inconsistency, as shown in Figure 8. Figure 9 shows the 
forest plot exploring this more consistent network.  
 
Please insert Figure 8 here. 
Please insert Figure 9 here. 
 
To investigate other potential sources of heterogeneity, further sensitivity analyses were conducted. 
First, analyses accounted for clinical characteristics of the studies samples. Because studies which 
excluded any form of psychiatric and/or medical condition co-occurring with insomnia were too few 
to perform a network meta-analysis, we indirectly evaluate the effect of this group of trials by 
excluding them from the analyses [49,54,70,78]. Results indicated significant effects of CBT-I 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
19 
 
individual (d= 0.43, 95% CI: 0.00 - 0.86). Q and I
2
 tests indicated high levels of heterogeneity (Q= 
65.48, df= 13, p<0.0001, I
2
= 80.1%).  
Furthermore, we considered other possible sources of heterogeneity including sex and age. Seven 
studies included exclusively female samples [43,45,55,58,59,70,79]. This did not warrant a network 
meta-analysis. We indirectly evaluated the effect of this group of trials by excluding it from the 
analyses. Results indicate significant effects of CBT-I individual (d= 0.66, 95% CI: 0.21 - 1.11). With 
respect to heterogeneity, Q value decreased but remained significant (Q= 31.11, df= 9, p<0.0002), 
and Higgins’s test resulted in a considerable level of heterogeneity (I
2
= 72%). 
Eight studies included exclusively elderly samples (i.e. age >60 years or defined as older adults 
sample in the title [41,51,53,54,58,68,76,78]). The limited number of studies did not allow for a 
network meta-analysis, and the effect of this group of trials was evaluated indirectly through 
exclusion from the analyses. Results indicate significant effects of pharmacotherapy (d= 1.15, 95% CI: 
0.23 – 2.07). Q and I
2
 tests revealed high levels of heterogeneity (Q= 39.28, df= 10, p<0.0001, 
I
2
=74.5%).   
To indirectly analyse the efficacy of self-help with or without professional contact, sensitivity 
analyses were conducted excluding specific groups of studies. First, analyses were performed 
excluding studies which used self-help with professional contact [64,65,68]. Results revealed a 
significant effect for CBT-I individual (d= 0.46, 95% CI: 0.05 - 0.87), with high heterogeneity (Q=58.05, 
df= 14, p<0.0001, I
2
= 75.9%). Second, analyses were performed excluding studies which used self-
help therapy without professional contact [45,62,70,73]. Results indicated significant effect only for 
CBT-I individual (d= 0.48, 95% CI: 0.03 - 0.93) with significant but decreased levels of heterogeneity 
(Q= 58.52, df= 12, p<0.0001, I
2
= 79.5%). 
Furthermore, analyses were conducted excluding the study with a high risk of bias [78]. Accordingly, 
results revealed a significant effect of CBT-I individual of medium magnitude (d= 0.41, 95% CI: 0.00 - 
0.82). Heterogeneity remained high (Q= 71.2, df= 16, p<0.0001, I
2
= 77.5%).  
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It was not possible to perform the analysis on specific group of studies according to the fatigue 
measure used due to a small number of studies. Nevertheless, it was possible to indirectly evaluate 
the effect of the multidimensional fatigue inventory, the most frequently used instrument, by 
excluding  11 studies using this scale [34,44,45,47,53,55,59,64,70,73] from the analysis. Results 
indicated no significant effects for any treatments. Heterogeneity levels remained significant (Q= 
39.18, df= 4 p< 0.0001, I
2
= 86.7%). Forest plots for all analyses are reported in Document S7.  
To further explore the role of the instrument in determining heterogeneity, we estimated whether 
the instruments were unequally distributed over the three comparisons: CBT-I Individual vs BT-I 
Individual, CBT-I Group vs BT-I Group, CBT-I Self-help vs BT-I Self-help. Fisher‘s exact test revealed no 
association between comparisons (p=0.571).  
 
Discussion 
The aim of the present systematic review and network meta-analysis was to synthesise the literature 
regarding the effectiveness of BT-I and CBT-I on  depressive and fatigue symptoms. After excluding 
inconsistent designs within the network, results showed that only individual CBT-I was associated 
with greater improvement at post-treatment compared with placebo on depressive symptoms, but 
not on fatigue. 
High heterogeneity between studies was found and markedly impacted our results. The source of 
heterogeneity could not be pinpointed despite investigating clinical and demographic variables, such 
as sex, age, comorbidity or risk of bias. With respect to outcome measures, we found that  
instruments were equally distributed across treatment types. Additionally, excluding studies that 
used the most frequently used scales, i.e., Beck depression inventory and the multidimensional 
fatigue inventory, did not substantially reduced heterogeneity. Thus, the choice of instrument did 
not notably contribute to heterogeneity. Nevertheless, the majority of the studies using the Beck 
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depression inventory [81] were associated with limited effectiveness 
[34,35,37,38,40,46,50,57,58,69,80].  
These results demonstrate an excessive amount variance in study designs, populations, and 
procedures which limits the impact of the evidence. Thus, it is imperative that clinical research on 
insomnia treatment moves towards establishing consistent (e.g. identifying target populations, 
adequate treatment settings and including strategies) and methodologically robust evidence (e.g. 
increasing power, using adequate recruitment procedures). Furthermore, efforts should be made to 
encourage replication studies in the field despite the challenges linked with publishing such work. 
Cognitive techniques embedded in treatment packages appear to contribute to treatment 
effectiveness. However, cognitive interventions within included studies were largely (n=29) [34-
37,39-43,54-50,54-57,59,60,62,65,68-74] limited to the cognitive restructuring of dysfunctional 
beliefs and attitudes about sleep according to Morin’s model [94]. Thus, future studies would benefit 
from including other techniques that may improve daytime symptoms such as paradoxical intention, 
cognitive control, emotion regulation training, behavioural activation and exercise. 
Group or self-help therapy both with and without professional contact seem to have limited effects 
on symptoms. A growing body of evidence from RCTs on group and self-help CBT-I demonstrate 
positive effects on depressive symptoms [45,66,72]. A comparison of treatments using network 
meta-analysis demonstrate less promising results. Nevertheless, in our review, due to the limited 
number of comparisons we were unable to perform analyses differentiating between booklet-based 
treatments and internet-based treatment.  
Individual CBT-I appears effective in reducing depressive symptoms and partially fatigue in those 
suffering from insomnia. These findings may corroborate the recently proposed hypothesis that CBT-I 
may have potential preventive properties for psychopathology, particularly for depression [6,11]. 
Sleep disturbances are widely spread in psychopathology [95] and insomnia is one of the most 
common mental disorders [2]. Yet, transdiagnostic models highlighted insomnia as a process 
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involved in the onset of several psychiatric disorders [96]. Accordingly, improving sleep and mood in 
patients with insomnia through CBT-I may have potential impact on the incidence of mental 
disorders and specifically on depression. The results of the present meta-analysis partially provide 
empirical support for this hypothesis. This may represent intriguing and challenging implications for 
insomnia therapy. However, it must be noted that most of the included samples in this review were 
without severe baseline levels of depression. Additionally, included studies were not designed to 
assess the effects of CBT-I in preventing depression. Finally, high heterogeneity further limits 
conclusions that can be drawn.  
With respect to study limitations, it is important to note that this review focussed on studies 
integrating at least SR in the treatment and excluded trials using SC only. However, a more 
comprehensive picture of treatment efficacy can be obtained from focussing on SC. It is 
recommended that future meta-analyses consider the effects of the two core behavioural strategies. 
Nevertheless, in line with the emerging literature on the standardisation of SR therapy [24], we 
decided to contribute to the debate aggregating empirical evidence on the efficacy of CBT-I 
integrating SR. 
A limitation of the present network meta-analysis is that a publication bias analysis was not possible. 
However, the conduct of publication bias analysis specifically in network meta-analysis is still yet to 
be established. Funnel plots, used in traditional meta-analysis to assess publication bias are not 
recommended for use in network meta-analysis where the direction of effects of small studies 
cannot be assumed [97]. This was the case for our study samples, composed of trials in which 
primary outcomes were sleep and insomnia severity while daytime symptoms of depression and 
fatigue were only secondary outcomes. Thus, there was minor risk of not publishing negative results. 
A further limitation of the present review is that the literature search relied on three databases. A 
more comprehensive literature research involving other databases may have provided a greater 
number of studies for this meta-analysis. Furthermore, grey literature was excluded in our review 
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which might have prevented the inclusion of potentially eligible studies, consequently affecting our 
results. 
Additionally, this review is limited to daytime depressive and fatigue symptoms, as these are two of 
the most common symptoms reported by patients [1,4,12]. However, future meta-analyses should 
consider other health-related variables such as quality of life and cognitive impairments.   
In conclusion, CBT-I may have a positive impact on  depressive and fatigue symptoms. However, the 
high variability between study methodologies and limited evidence regarding efficacy on fatigue 
symptoms, suggest that the review findings are interpreted with caution. Future research on 
insomnia would benefit from addressing these gaps in order to further strengthen the empirical 
evidence base on the effectiveness of CBT-I.  
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Practice points 
1. The effectiveness of standard psychological treatments for insomnia on 
daytime depressive and fatigue symptoms remains poorly investigated.  
2. Results from meta-analysis highlighted an overall high level of 
heterogeneity between studies that was only partially explained by clinical 
and demographic characteristics of the samples. 
3. Findings suggest that CBT-I appears to positively impact daytime 
symptoms when administered individually.  
Research agenda 
1. Daytime symptoms of insomnia should be included as primary outcomes in 
future trials. 
2. Studies should describe randomisation and blinding procedures in detail to 
decrease risk of bias.  
3. Replication studies should be encouraged. Future randomised controlled 
trials should be conducted with larger samples to increase statistical power.  
4. Settings and treatment strategies should be better operationalised and 
common experimental procedures should be shared. 
5. Future randomised controlled trials should test the long-term effects of 
psychological therapies for insomnia on daytime symptoms. 
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Figures Legend: 
Figure 1: Search flow.  
Figure 2: Network graph depression. BT-I= behavioural therapy for insomnia, CBT-I = cognitive 
behavioural therapy for insomnia.  
Figure 3: Net heat plot of depressive. BT-I= behavioural therapy for insomnia, CBT-I = cognitive 
behavioural therapy for insomnia.  
Figure 4: Net heat plot depression after sensitivity analyses. BT-I= behavioural therapy for insomnia, 
CBT-I = cognitive behavioural therapy for insomnia.  
Figure 5: Forest plot depression after sensitivity analyses. 
Number of studies: 29 
Number of treatments: 11 
Number of pairwise comparisons: 35 
Heterogeneity tests: Q= 64.14, df= 22, p<0.0001,I
2
= 65.7% 
Legend: BT-I= behavioural therapy for insomnia, CBT-I= cognitive behavioural therapy for insomnia, 
CI= confidence intervals, DF= degrees of freedom. 
 
Figure 6: Network graph fatigue. BT-I= behavioural therapy for insomnia, CBT-I = cognitive 
behavioural therapy for insomnia.  
Figure 7: Net heat plot fatigue. BT-I= behavioural therapy for insomnia, CBT-I = cognitive behavioural 
therapy for insomnia.  
Figure 8: Net heat plot fatigue after sensitivity analyses.BT-I= behavioural therapy for insomnia, CBT-I 
= cognitive behavioural therapy for insomnia.  
Figure 9: Forest plot fatigue after sensitivity analyses. 
Number of studies: 18 
Number of treatments: 11 
Number of pairwise comparisons: 22 
Heterogeneity tests: Q= 36.63, df= 10, p<0.0001, I
2
= 72.7%. 
Legend: BT-I= behavioural therapy for insomnia, CBT-I= cognitive behavioural therapy for insomnia, 
CI= confidence intervals, DF= degrees of freedom. 
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Age CBT (means) Age controls
Sex CBT 
(%Female)
Sex  controls
46.2 (means) 33.3 (%Female)
49.6 46.1 59.7 37.5
51.9 50.3 38.4 56.4
57 48.7 54 46.1
45 57.2727273 59 54.5555556 55 3894.59091 62.8 3717.6087
43.3 45 30 82.80% 55 79%
57.2 43.3 100 30
64.5 59.2 62.5 100
55.8 67.6 44 50
50.1 55.1 95.7 48
55.7 47.4 52.1 94.4
68.7 52.4 64.4 36.3
61 69.5 69 64
49 61 73.1 68
58.7 49 79 73.1
70.2 60.3 71.4 62
41.5 70.2 17-Jun 71.4
38.6 41.5 39.9 10-Jan
78 38.6 78 69
58.9 66.3 58.9 68.3
49.1 53.6 75.8 66.6
52 45.4 78.9 40
65 43 22-Feb 88.8
51.7 60 71.5 22-Feb
67.9 51.9 70.8 68
64 68 50 71.4
36.4 64 10 50
46.5 39.1 100 10
52.1 48.6 100 100
36.4 52.8 43 100
47.7 72.6 58.3 80
43.9 56.9 100 61.1
63 50.2 69.4 100
62.5 66.3 50 63.2
49 62.5 65.6 50
50.7 42 66.6 66.7
64.5 50.7 100 66.6
53.7 67.4 100 33.5
70.1 59.6 60.8 71.4
54.8 67.7 100 73.9
53.9 53.3 100 100
37.1 55.4 75.9 100
45.7 37.3 90 56.3
47 51.3 33.3 90
48.7 50.2 59.3 44.4
n.s 50.1 67.8 81.4
69.2 n.s 78.2 66.1
66.5 96.4
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Table 1. Study characteristics. 
Study Insomnia 
according to
Insomnia 
duration
Mental comorbidity Physical comorbidity Sleep 
comorbidity
Drug use N CBT-I N controls Age CBT M 
(SD/range)
Age controls M 
(SD/range)
 CBT-I % 
females
Controls % 
females
Risk of 
bias
Depression 
measure
Fatigue 
measure
Arnedt et al. 2011 [34] ISI NS Alcohol dependence Excluded Excluded Sleep 9 8                     46.2 (8.9)
                         
46.1 (12.0)
                   
33.3 37.5 Low BDI MFI
Bjorvatn et al. 2011 [60] BIS NS NS NS Excluded Sleep and others 77 78                     49.6 (14.5)
                         
50.3 (13.2)
                  
59.7 56.4 Moderate HADS ̶―
Blom et al. 2015 [61] AASM, DSM NS Major depression NS Excluded Sleep and others 22 21 46.1 (13.6) 48.2 (11.0) 35 65 Low MADRS-S ̶―
Chen et al. 2008 [49] DSM NS Excluded Excluded Excluded Sleep 13 13                     51.9 (8.6)
                         
48.7 (14.6)
                  
 38.4 46.1 Moderate ̶― FSS
Chen et al. 2011 [62] DSM <1 year Excluded Hemodialysis Excluded NS 37 35 57 (9.0) 59 (11.0) 54 62.8 Low BDI FSS
Currie et al. 2000 [50] DSM >1 year Mood disorders Chronic pain Excluded Psychotropic and 
others 32 28 45 (8.0) 45 (8.0) 55 55 Moderate BDI ̶―
Currie et al. 2004 [35]* DSM NS Alcohol dependence NS NS Sleep and others 40 20                     43.3 (10.9)
                         
43.3 (10.9) 30 30 Moderate BDI ̶―
Dirksen & Epstein 2008 
[79] DSM, ICSD >1 year NS Breast cancer survivors Excluded Sleep and others 34 38
                    
57.2 (9.9)
                         
59.2 (10.7) 100 100 Moderate CES-D POMS/FI
Edinger et al. 1996 [76] ISQ < 1 year NS NS PLMD Excluded 8 8                     64.5 (4.1)
                         
67.6 (4.1)
                   
  62.5 50 Low ̶― ISQ-DF
Edinger et al. 2001 [80]* DSM >1 year Partially excluded Excluded Excluded Excluded 25 50                     55.8 (12.1)
                         
55.1 (11.5) 44 48 Low BDI ̶―
Edinger et al. 2005 [36]* DSM NS Excluded Pain Excluded Psychotropic and 
others 18 29
                    
50.1 (6.9)
                         
47.4 (9.0)
                  
 95.7 94.4 Low POMS ̶―
Edinger et al. 2007 [37] DSM < 1 year Excluded Excluded Excluded Excluded 39 9                     55.7 (10.2)
                         
52.4 (7.3)
                   
  52.1 36.3 Moderate BDI ̶―
Epstein et al. 2012 [77] DSM < 1 year Excluded Excluded Excluded Excluded 129 50                     68.7 (7.7)
                         
69.5 (8.3)
                   
  64.4 64 Moderate GDS ̶―
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Espie et al. 2008 [51] DSM >1 year Marginal depression Cancer Excluded Sleep 100 50 60.5 (53.3-70) 58 (52-68) 69 68 Low HADS FSI
Espie et al. 2014 [63]* DSM >1 year Excluded Excluded Excluded Sleep and others 55 109 49 (18-78) 49 (18-74)                    
  73.1 73.1 Low DASS ̶―
Garland et al. 2014 [52] DSM >1 year Excluded Cancer Excluded Psychotropic and 
others 40 32
                    
58.7 (10.4)
                         
60.3 (12.2) 79 62 Low POMS ̶―
Germain et al. 2006 [75] DSM >1 year Depression, anxiety
Arthritis, cancer, joint, 
cardiovascular and 
bladder diseases
Excluded Sleep 17 18                     70.2 (5.3)
                         
70.2 (5.3)
                   
  71.4 71.4 Low HAM-D ̶―
Germain et al. 2012 [38]* DSM NS PTSD Excluded Partially 
excluded Other 17 33
                    
40 (14.1)
                         
41.5 (12.9) 17.6 10.1 Low BDI ̶―
Ho et al. 2014 [64] DSM >1 year Depression, GAD, panic 
and bipolar disorder
Respiratory disease, pain, 
cardiovascular disease, 
diabetes
Marginal Other 207 105                     38.6 (11.8) 39.9 (12.7)
                   
  39.9 69 Moderate HADS MFI
Irwin et al. 2014 [53]* DSM, ICSD NS Excluded Cardiovascular disease Excluded Excluded 50 73 64.4 (6.1)                          66.3 (7.4) 78 68.3 Low IDS-C MFSI
Jansson-Fröjmark et al. 
2012 [39] DSM >1 year
Depression, GAD, social 
phobia Hearing impairment Excluded Sleep 17 15 57.8 (6.6)
                         
53.6 (10.4)
                   
  58.9 66.6 Moderate HADS ̶―
Jernelöv et al. 2012 [65] RDC >1 year Marginal depression and 
anxiety
Marginal allergic disease, 
pain, stress
RLS, snoring, 
bruxism Sleep 89 44
                    
49.1 (12.5)
                         
45.4 (16.0)
                   
  75.8 40 Low ̶― DTF
Jungquist et al. 2010 [40] DSM >1 years NS Chronic pain Excluded Other 19 9 52 (9.9) 43 (10.7)                   
 78.9 88.8 Low BDI ̶―
Kapella et al. 2011 [41] SII, PSG NS Excluded Chronic obstructive polumary disease Excluded Excluded 9 9 65 (9.0) 60 (10.0) 22.2 22.2 Moderate POMS CRQ-FS
Lancee et al. 2012 [66] DSM NS Excluded NS Partially 
excluded Sleep 417 200
                    
51.7 (12.1)
                          
51.9 (12.2)
                   
  71.5 68 Low CES-D ̶―
Lichstein et al. 2001 [78]* ASDA >1 year Excluded Excluded Excluded Excluded 24 50                     67.9 (6.7) 68 (7.1)
                   
  70.8 71.4 High ̶― FSS
Lovato et al. 2014 [54] DSM >1 year Excluded Excluded Excluded Excluded 89 32 64 (NS.) 64 (NS.) 50 50 Moderate ̶― Flinder fatigue scale
Margolies et al. 2013 [42] DSM NS PTSD Excluded Excluded Sleep 15 12                     36.4 (9.3)
                         
39.1 (8.9) 10 10 Moderate PHQ ̶―
Martinez et al. 2013 [55] DSM >1 year Excluded Fibromyalgia Excluded Other 30 29                     46.5 (6.3)
                         
48.6 (7.2) 100 100 Low ̶― MFI
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Matthews et al. 2014 [43] DSM, ISI NS Excluded Cancer Excluded Excluded 30 30                     52.1 (6.8)
                         
52.8 (7.7) 100 100 Low HADS PFS
McCurry et al. 1998 [33] Jenkins scale NS NS Excluded Excluded Excluded 21 15 66.4 (10.4)                          72.6 (7.7) 43 80 Low CES-D ̶―
Mimeault & Morin 1999 
[67]
DSM, 
ASDA, ISI >1 year Partially excluded Excluded Excluded Sleep 36 18
                    
47.7 (10.8)
                         
56.9 (13.4)
                   
  58.3 61.1 High BDI ̶―
Miro´et al. 2011 [56] DSM >1 year Partially excluded Excluded Excluded Other 16 15                     43.9 (6.0)
                         
50.2 (6.1) 100 100 Low HADS ̶―
Morgan et al. 2012 [68] DSM NS NS Chronic disease Excluded Sleep 98 95 67 (7.9)                          66.3 (6.9)
                  
 69.4 63.2 Low ̶― FSS
Morin et al. 2004 [57] DSM >1 year Excluded Excluded Excluded Benzodiazepine 
tapering 24 25 61.4 (6.4)
                         
62.9 (4.7) 50 50 Moderate BDI ̶―
Morin et al. 2005 [69] DSM, ISI >1 year NS NS Excluded Sleep 96 96 49 (15.3) 45.9 (14.2)                   
 65.6 66.7 Low BDI ̶―
Pigeon et al. 2012 [44]* DSM NS Excluded Chronic pain Excluded NS 6 9                     50.7 (8.3)
                          
50.7 (8.3)
                  
 66.6 66.6 Moderate CES-D MFI
Rios Romenets et al. 2013 
[58]* ISI NS NS Parkinson´s disease
Partially 
excluded Excluded 6 12
                    
64.5 (16.3)
                          
67.4 (10.5) 100 33.5 Moderate BDI
Krupp 
fatigue scale
Ritterband et al. 2012 [70] DSM >1 year Excluded Excluded NS Excluded 14 14                     53.7 (10.8)
                         
59.6 (12.3) 100 71.4 Moderate ̶― MFSI-SF
Rybarczyk et al. 2005 [71] DSM NS Excluded
Osteoarthritis, coronary 
artery and pulmonary 
diseases
Excluded Sleep and others 46 46                     70.1 (9.1)
                         
67.7 (7.9)
                  
 60.8 73.9 Low POMS ̶―
Savard et al. 2005 [59] DSM, ICSD >1 year Depression, GAD, 
adjustment disorders
Cancer and not specified 
other physical 
comorbidities
Excluded Sleep 27 30                     54.8 (7.0)
                         
53.3 (7.7) 100 100 Low HADS MFI
Savard et al. 2014 [45]* ISI >1 year Anxiety, adjustment, mood disorders
Not specified other 
comorbidities Excluded Sleep 161 81
                    
53.9 (8.8)
                         
55.4 (8.8) 100 100 Low HADS MFI
Talbot et al. 2014 [46] RDC NS PTSD, depression and 
other not specified NS
Partially 
excluded Psychotropic 29 16
                    
37.1 (10.4)
                         
37.3 (11)
                  
 75.9 56.3 Low BDI ̶―
Tang et al. 2012 [47] ISI >1 year
Depression, social phobia, 
substance dependence, 
PTSD, GAD
Chronic pain Excluded Sleep and others 10 10                     45.7 (9.3)
                         
51.3 (7.9) 90 90 Moderate HADS MFI
Ulmer et al. 2011 [48] ISI NS PTSD NS Excluded Sleep and others 9 9 47 (9.4)                          50.2 (11.6)
                  
 33.3 44.4 Moderate PHQ ̶―
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van Straten et al. 2013 [72] DSM >1 year Partially excluded NS NS Sleep 59 59                     48.7 (13.8)
                         
50.1 (11.9)
                  
 59.3 81.4 Moderate CES-D ̶―
Vincent et al. 2009 [73] RDC NS Depression,  panic, social phobia, GAD, OCD NS
Sleep apnea, 
plmd, RLS, 
parasomnia
Sleep 59 59                      NS
                          
NS
                  
 67.8 66.1 Low ̶― MFI
Vitiello et al. 2009 [74] DSM >1 year Partially excluded Osteoarthritis Partially 
excluded Sleep and others 23 28
                    
69.2 (8.9)
                         
66.5 (7.7)
                  
 78.2 96.4 Moderate GDS ̶―
Abbreviation: AASM= American academy of sleep medicine; ASDA= American sleep disorders association; BDI= Beck depression inventory; BIS= Berger insomnia scale; CBT= cognitive behavioral therapy; CBT-I= cognitive behavioral therapy for insomnia; CES-D= 
center for epidemiological studies depression scale; CRQ-FS= chronic respiratory disease questionnaire-fatigue scale; DASS= depression anxiety stress scale; DSM= Diagnostic and statistical manual of mental disorder; DTF= daytime fatigue scale; FSI= fatigue symptom 
inventory; FSS= fatigue severity scale; GAD= generalized anxiety disorder; GDS= geriatric depression scale; HADS= hospital anxiety and depression scale; HAM-D= Hamilton depression rating scale; ICSD= International classification of sleep disorders; IDS-C= inventory 
of depressive symptomatology; ISI= insomnia severty index; ISQ-DF= insomnia severity questionnaire-daytime fatigue scale;  ISQ=insomnia severity questionnaire; MADRS-S= MontgomeryÅsberg depression rating scale; MFI= multidimensional fatigue inventory; MFSI= 
multidimensional fatigue symptom inventory; MFSI-SF=  multidimensional fatigue symptom inventory-short form; NS= not specified; OCD= obsessive compulsive disorder; PFS= Piper fatigue scale; PHQ= patient health questionnaire; PLMD= periodic limb movement 
disorder; POMS= profile of mood states; POMS-FI= profile of mood states-fatigue inertia scale; PSG= polysomnography; PTSD= post-traumatic stress disorder; RDC= research diagnostic criteria; RLS= restless legs syndrome; SD= standard deviation; SII= sleep 
impairment index. Multi-arm studies are marked with *. For multi-arm studies pooled data is reported. 
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From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
 
Figure 1. Search flow. 
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Additional records identified 
through other sources 
(n =333) 
Records screened 
(n =129) 
Records excluded 
(n = 81)  
-No trials (5); 
-Not including control group (20); 
-Not including SRT/SC (5); 
-Not including adult insomnia 
patients (12); 
-No measures of depression or 
fatigue (39).  
 
Studies included in 
qualitative synthesis 
(n =48) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =47) 
Records excluded 
(n = 1)  
-Intervention combined both 
individual and group therapy. 
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Figure 5. Forest plot depression after sensitivity analyses.
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Figure 9. Forest plot fatigue after sensitivity analyses.
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